Nanopore-based molecular sensing technology company Oxford Nanopore Technologies plc (LSE: ONT) announced on Monday that it will sequence 10,000 genomes for Singapore's National Precision Medicine (NPM) programme. This project, led by Precision Health Research, Singapore (PRECISE), aims to catalogue structural variants across Singapore's diverse population, including Malay, Indian and Chinese communities.

The Oxford Nanopore platform was chosen for its scalability and flexibility in sequencing both short and ultra-long DNA/RNA fragments. It can detect methylation without additional steps, delivering faster results than other platforms. This initiative highlights Oxford Nanopore's commitment to enhancing genetic research, particularly for ethnically diverse groups underrepresented in genomic databases.

Commencing mid-2024, the project is expected to last approximately 12 months. This effort aligns with NPM Phase II, which aims to transform healthcare in Singapore through insights into the Asian genome and data-driven healthcare solutions. Oxford Nanopore's platform supports real-time, high-performance, scalable analysis and is used in over 120 countries.

NPM Phase II plans to study the genetic makeup of 100,000 healthy Singaporeans and specific patient cohorts. Genetic data will be integrated with lifestyle, environmental and clinical data to provide insights into Asian diseases. The programme will also strengthen the precision medicine sector in Singapore by attracting overseas companies and creating opportunities for local businesses.

PRECISE collaborates with Singapore research and clinical partners, including A*STAR, Lee Kong Chian School of Medicine, National Healthcare Group, National University Health System, National University of Singapore and SingHealth Duke-NUS Academic Medical Centre. Supported by the National Research Foundation, Singapore, and administered by the Ministry of Health, PRECISE is part of the Consortium for Clinical Research and Innovation, Singapore. Oxford Nanopore has confirmed that there is no change to its 2024 or medium-term financial guidance as a result of this project.